New insulin application systems: does one contribute more than another?
DOI:
https://doi.org/10.47196/diab.v56i3Sup.489Keywords:
insulin, systemsAbstract
The ideal or most appropriate insulin therapy system is one that achieves or comes close to maintaining blood glucose within normal physiological ranges. Reaching this goal is the current challenge in Biotechnology applied to Diabetes. The developments of rapid analog insulins, continuous glucose monitoring (CGM) and continuous subcutaneous insulin infusers (CSII) were and are simultaneously and progressively providing the necessary tools to approach the long-awaited goal. However, the paradigm to make this possible arose from the automated insulin delivery (AID) or artificial páncreas (AP) systems, in which engineering added to advances in CSII and CGM, a third component called "control algorithm" who regulates the administration of insulin by the infuser according to the value of interstitial glucose transmitted by the CGM.
References
I. Holt R, DeVries JH, Hess-Fischl A, et al. The management of type 1 diabetes in adults. A consensus report by the Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2021:44(11):2589-2625. doi1.2337/dci21-0043.
II. Diabetes Technology: Standards of Medical Care in Diabetes. Diabetes Care 2022 Jan 1,45(S1):S97-S112. doi:10.2337/dc22-S007.
III. Bass M, Teliti M, Lezzi M, Magg D, et al. A comparison of two hybrid vlosed-loop systems in Italian children and adults with type 1 diabetes. Front Endocrinol 18 Jan 2022;12. doi: 10.3389/fendo2021.802419.
IV. Boughton CK, Hovorka R. The artificial pancreas. Curr Opin Organ Transplant 2020; 25:336-342. doi:10.1097/MOT.0786.
V. Garelli F, Fushini E, Grosembacher L, et al. First outpatient clinical trial of a full closed-loop artificial pancreas system in South America. J Diabetes Sci Technol 2022 May 12. doi: 10.1177//19322968221096162.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 on behalf of the authors. Reproduction rights: Argentine Diabetes Society
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.
La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.
Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.
